Economic evaluation of donepezil in moderate to severe Alzheimer disease

被引：0
|
作者：
van Hout, HPJ
Bosmans, JE
Stalman, WAB
机构：
来源：
NEUROLOGY | 2005年 / 64卷 / 07期
关键词：
D O I：
10.1212/WNL.64.7.1320
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1320 / 1320
页数：1
相关论文
共 50 条
  • [31] Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial
    Tariot, PN
    Farlow, MR
    Grossberg, GT
    Graham, SM
    McDonald, S
    Gergel, I
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (03): : 317 - 324
  • [32] Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
    Steven H Ferris
    Frederick A Schmitt
    Judith Saxton
    Sharon Richardson
    Joan Mackell
    Yijun Sun
    Yikang Xu
    Alzheimer's Research & Therapy, 3
  • [33] Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
    Molino, Ivana
    Colucci, Luisa
    Fasanaro, Angiola M.
    Traini, Enea
    Amenta, Francesco
    SCIENTIFIC WORLD JOURNAL, 2013,
  • [34] Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil - An exploratory reanalysis
    Schmitt, Frederick A.
    van Dyck, Christopher H.
    Wichems, Christine H.
    Olin, Jason T.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2006, 20 (04): : 255 - 262
  • [35] The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review
    Buck, Austin
    Rezaei, Kayvon
    Quazi, Aman
    Goldmeier, Gary
    Silverglate, Bret
    Grossberg, George T.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (06) : 607 - 614
  • [36] DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT
    Jones, Rob
    Sheehan, Bart
    Phillips, Patrick
    Juszczak, Ed
    Adams, Jessica
    Baldwin, Ashley
    Ballard, Clive
    Banerjee, Sube
    Barber, Bob
    Bentham, Peter
    Brown, Richard
    Burns, Alistair
    Dening, Tom
    Findlay, David
    Gray, Richard
    Griffin, Mary
    Holmes, Clive
    Hughes, Alan
    Jacoby, Robin
    Johnson, Tony
    Jones, Roy
    Knapp, Martin
    Lindesay, James
    McKeith, Ian
    McShane, Rupert
    Macharouthu, Ajay
    O'Brien, John
    Onions, Caroline
    Passmore, Peter
    Raftery, James
    Ritchie, Craig
    Howard, Rob
    TRIALS, 2009, 10
  • [37] DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
    Rob Jones
    Bart Sheehan
    Patrick Phillips
    Ed Juszczak
    Jessica Adams
    Ashley Baldwin
    Clive Ballard
    Sube Banerjee
    Bob Barber
    Peter Bentham
    Richard Brown
    Alistair Burns
    Tom Dening
    David Findlay
    Richard Gray
    Mary Griffin
    Clive Holmes
    Alan Hughes
    Robin Jacoby
    Tony Johnson
    Roy Jones
    Martin Knapp
    James Lindesay
    Ian McKeith
    Rupert McShane
    Ajay Macharouthu
    John O'Brien
    Caroline Onions
    Peter Passmore
    James Raftery
    Craig Ritchie
    Rob Howard
    Trials, 10
  • [38] Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
    Ferris, Steven H.
    Schmitt, Frederick A.
    Saxton, Judith
    Richardson, Sharon
    Mackell, Joan
    Sun, Yijun
    Xu, Yikang
    ALZHEIMERS RESEARCH & THERAPY, 2011, 3 (03):
  • [39] The benefits of donepezil in patients with moderate-to-severe Alzheimer's disease are independent of baseline dementia severity
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Xu, Y
    Ieni, J
    Schwam, E
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 258 - 258
  • [40] Severe Alzheimer's disease: benefits of donepezil therapy
    Winblad, Bengt
    INTERNATIONAL PSYCHOGERIATRICS, 2006, 18 : S25 - S31
12345